Several pipeline drugs that are in late-stage development may help address these longstanding unmet needs. KOLs expressed excitement over continuous subcutaneous levodopa infusion systems offered by AbbVie’s ABBV-951 (foscarbidopa/foslevodopa) and NeuroDerm’s ND0612 (levodopa/carbidopa) to control motor fluctuations in a non-invasive way. Sunovion’s ulotaront, a novel oral non-D2 receptor antagonist that acts by modulating the activity of trace amine-associated receptor 1 through a different mechanism of action than current antipsychotic drugs, is being investigated for PD psychosis.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,